Celiac Plexus Radiosurgery for Pain Management

Status Recruiting

Clinical Trial Summary

This prospective study evaluates celiac plexus radiosurgery for pain control in patients with upper abdominal malignancies.

Clinical Trial Description

This study aims as primary objective to evaluate short and long term pain relief following the administration of radiosurgery to the celiac plexus in patients with upper abdominal cancer. As secondary objectives it will describe acute and late side effects and quality of life measures of patients undergoing the treatment.

The study has a prospective, single arm design. It will be composed from an initial run-in safety assessment that will include 6 patients and then continue as a phase II trial. All eligible patients will receive the same protocol of celiac plexus radiosurgery and will be evaluated before, during and following this treatment.

The treatment duration is one and a half weeks (5 fractions delivered every other weekday). ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02356406
Study type	Interventional
Source	Sheba Medical Center
Contact	David Hausner, M.D
Phone	972-35302542
Email	david.hausner@sheba.health.gov.il
Status	Recruiting
Phase	Phase 2
Start date	January 2014
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06026774` - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms	Phase 1
Recruiting	`NCT06019702` - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms	Phase 1
Recruiting	`NCT06026800` - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms	Phase 1
Completed	`NCT02909452` - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT05602935` - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study	Phase 2
Recruiting	`NCT04518852` - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC	Phase 2
Completed	`NCT03717298` - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma	Phase 2
Recruiting	`NCT05322486` - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Recruiting	`NCT04556344` - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer	N/A
Terminated	`NCT03306693` - Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers	N/A
Active, not recruiting	`NCT01037049` - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks	Phase 2
Recruiting	`NCT02208804` - Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization	Phase 2/Phase 3
Completed	`NCT04080843` - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients	Phase 2
Recruiting	`NCT03303495` - A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC	Phase 3
Terminated	`NCT04644315` - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	Phase 2
Recruiting	`NCT03271255` - Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)	Phase 2
Recruiting	`NCT03221335` - EUS-guided RFA for Solid Abdominal Neoplasms	N/A
Recruiting	`NCT02487017` - DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT01556815` - Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT04949282` - Spanish Series of Patients Treated With the Radionuclide Lutetium177